Research ArticleClinical Studies
Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review
MARIA DIMOU, AIKATERINI BITSANI, WOLFGANG BETHGE, PANAYIOTIS PANAYIOTIDIS and THEODOROS P. VASSILAKOPOULOS
In Vivo November 2021, 35 (6) 3401-3406; DOI: https://doi.org/10.21873/invivo.12639
MARIA DIMOU
1First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece;
AIKATERINI BITSANI
1First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece;
WOLFGANG BETHGE
2Department Hematology & Oncology Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany;
PANAYIOTIS PANAYIOTIDIS
1First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece;
THEODOROS P. VASSILAKOPOULOS
3Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
In this issue
In Vivo
Vol. 35, Issue 6
November-December 2021
Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review
MARIA DIMOU, AIKATERINI BITSANI, WOLFGANG BETHGE, PANAYIOTIS PANAYIOTIDIS, THEODOROS P. VASSILAKOPOULOS
In Vivo Nov 2021, 35 (6) 3401-3406; DOI: 10.21873/invivo.12639
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.